Hypertension is one of the most important independent risk factors for the prognosis of
maintenance hemodialysis patients. The incidence rate is high and the control rate is low.
Nocturnal hypertension has been paid more attention in recent years. Compared to daytime
blood pressure, nocturnal blood pressure is an independent and efficient prognostic indicator
of hypertensive deaths and cardiovascular events, but it's lack of evidence about its impact
on prognosis in hemodialysis patients and the effective treatment program. Our previous
cohort study suggests that the incidence of nocturnal hypertension in patients with chronic
kidney disease is up to 71.22%, with a significant increase as the decline of renal function,
and more severe target organ damage in patients with nocturnal hypertension: the decrease of
glomerular filtration rate, left ventricular hypertrophy, and the increase of all cause death
and cardiovascular death. Our small sample size study show that night time antihypertensive
drugs can better control blood pressure and delay the development of left ventricular
hypertrophy. These preliminary results suggest that nocturnal hypertension is closely related
to the prognosis of chronic renal disease. Taking antihypertensive drugs at night is one of
the options for controlling nocturnal hypertension. However, it is not clear whether taking
antihypertensive drugs at night can improve the prognosis of maintenance hemodialysis
patients with nocturnal hypertension. To this end, we collect maintenance hemodialysis
patients with nocturnal hypertension, and propose a time selective use of valsartan to
intervene in nocturnal hypertension. By comparing the differences in the effects of valsartan
on the prognosis of maintenance hemodialysis patients during the day or night, to further
clarify the role of nocturnal hypertension in the prognosis of maintenance hemodialysis
patients, whether controlling nocturnal hypertension can improve the prognosis of maintenance
hemodialysis patients. The completion of the study will optimize the prevention and treatment
of hypertension in maintenance hemodialysis patients, and provide an evidence for precise
prevention and treatment of hypertension in maintenance hemodialysis patients.